Epimeth Tablet contains Epalrestat 150 mg, an aldose reductase inhibitor used primarily in the management of diabetic neuropathy. Epalrestat acts by inhibiting the enzyme aldose reductase, which plays a key role in the polyol pathway responsible for converting glucose into sorbitol. In diabetic patients, excessive sorbitol accumulation in nerves, lenses, and kidneys contributes to diabetic complications such as neuropathy, retinopathy, and nephropathy. By reducing sorbitol formation, Epimeth helps to prevent or delay the progression of nerve damage associated with chronic hyperglycemia. This medication is indicated for patients with diabetic peripheral neuropathy, presenting symptoms such as numbness, burning sensation, and pain in the extremities. Epimeth Tablet is generally well tolerated, with adverse effects being rare but may include gastrointestinal discomfort, rash, or elevated liver enzymes. It should be administered under medical supervision, with dosage adjustments considered in patients with hepatic or renal impairment. Epimeth is intended as an adjunct to optimal glycemic control and should not replace standard diabetes management practices. Regular monitoring of liver function tests is recommended during prolonged therapy to ensure safety and efficacy.